SCHEMBL29567713

SCHEMBL29567713

FC(F)(F)C(CCN1CCOCC1)c1ccc(-n2cc(-c3ccnc4[nH]cnc34)cn2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.42
▸ GRM4 Q14833 2/20 0.36
▸ KDM4A O75164 4/20 0.34
▸ KDM4B O94953 4/20 0.34
▸ KDM5C P41229 4/20 0.34
▸ KDM5B Q9UGL1 4/20 0.34
▸ CCNT1 O60563 3/20 0.33
▸ CDK9 P50750 3/20 0.33
▸ MKNK1 Q9BUB5 3/20 0.32
▸ LRRK2 Q5S007 2/20 0.32
▸ MELK Q14680 1/20 0.32
▸ NEK1 Q96PY6 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP3A4 P08684 1/20 0.31
▸ CYP2D6 P10635 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31
▸ HIF1A Q16665 1/20 0.31
▸ CCNC P24863 1/20 0.31
▸ CDK8 P49336 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22736186 1.00 MAPK1 (0.42) MAPK1GRM4KDM4AKDM4BKDM5C
SCHEMBL29567579 0.92 MAPK1 (0.38) MAPK1GRM4KDM4AKDM4BKDM5C
SCHEMBL22736009 0.92 MAPK1 (0.38) MAPK1GRM4KDM4AKDM4BKDM5C
SCHEMBL22735748 0.91 MELK (0.34) MAPK1KDM4AKDM4BKDM5CKDM5B
SCHEMBL29567596 0.91 MELK (0.34) MAPK1KDM4AKDM4BKDM5CKDM5B
SCHEMBL22736180 0.86 MAPK1 (0.34) MAPK1GRM4KDM4AKDM4BKDM5C
SCHEMBL29567903 0.86 MAPK1 (0.34) MAPK1GRM4KDM4AKDM4BKDM5C
SCHEMBL22736182 0.86 JAK2 (0.32) —
SCHEMBL22736024 0.85 GRM4 (0.36) MAPK1GRM4CCNCCDK8
SCHEMBL22716928 0.85 GRM4 (0.33) MAPK1GRM4KDM4AKDM4BKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3976612-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD (IN) 2022-04-06 — — EP claimed
US-12516056-B2 Compounds for inhibition of janus kinase 1 MANKIND PHARMA LTD. (IN) 2026-01-06 — — US disclosed
US-20220235046-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD. (IN) 2022-07-28 — — US disclosed
EP-3976612-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD (IN) 2022-04-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235046-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 JAK1, JAK2, JAK3 MAPK1 20/4885GRM4 2623/4885KDM4A 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback